Edit |   |
---|---|
Product Name | CD13 Antibody Kit, anti-human, APC, REAlease® |
Description | CD13 Antibody Kit, anti-human, APC, REAlease®. Clone REAL312 is an antibody fragment derived from the full CD13 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity. | Clone REAL312 recognizes the CD13 antigen, a type II transmembrane glycoprotein, which is also known as aminopeptidase N or gp150. CD13 is expressed on granulocytes, myeloid progenitors, endothelial cells, epithelial cells, and subset of granular lymphoid cells. It is also broadly expressed in other tissues such as kidney proximal tubules, intestine, and placenta. CD13 is an enzyme that is used as a biomarker to detect damage to the kidneys. It also serves as a receptor for one strain of human coronavirus that is an important cause of upper respiratory tract infections. Defects in CD13 appear to be a cause of various types of leukemia or lymphoma. | The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes. |
Size | 100 tests |
Concentration | 1:50 |
Applications | Flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry |
Other Names | ANPEP, APN, gp150, LAP1, p150, PEPN |
Gene, Accession, CAS # | n/a |
Catalog # | 130-122-636 |
Price | $440 |
Order / More Info | CD13 Antibody Kit, anti-human, APC, REAlease® from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Look, A. T. et al. (1989) Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J. Clin. Invest. 83 (4): 1299-1307. | Yeager, C. L. et al. (1992) Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 357 (6377): 420-422. | Favaloro, E. J. et al. (1993) CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated. Exp. Hematol. 21 (13): 1695-1701. |